US2006024764A1PendingUtilityA1
Proteins producing an altered immunogenic response and methods of making the same
Individually held — no corporate assignee on recordPriority: Apr 15, 1998Filed: Dec 22, 2004Published: Feb 2, 2006
Est. expiryApr 15, 2018(expired)· nominal 20-yr term from priority
G01N 33/6854A61K 38/00C12N 9/20C12N 9/54C12N 9/6424C12Y 302/01004G01N 33/505C12N 9/2437
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein. Alternatively, T-cell epitopes are mutated to produce increased immunogenic reactions. Moreover, naturally occurring proteins are provided.
Claims
exact text as granted — not AI-modified1 - 10 . (canceled)
11 . A nucleic acid encoding a variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest, wherein said T-cell epitope of said polypeptide of interest is altered to produce said variant, and wherein said polypeptide of interest is an enzyme selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrases, reductase, oxidase, isomerase, transferase, kinase and phosphatase.
12 . An expression vector comprising the nucleic acid of claim 11 .
13 . A host cell transformed with the expression vector of claim 12 .
14 - 28 . (canceled)Join the waitlist — get patent alerts
Track US2006024764A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.